Advertisement Webinar: Co-crystals and Chemistry Characterisation Optimisation - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More

Malvern Panalytical

Particle Size and Shape Analysis, Zeta Potential and NIR-Chemical Imaging.

More info about Malvern Panalytical

Webinar: Co-crystals and Chemistry Characterisation Optimisation

Malvern Panalytical has announced that its partner Concept Life Sciences will be hosting a new webinar titled ‘Pharmaceutical Co-crystals and Chemistry Characterisation Optimisation of Drug Properties’.

Taking place on 27 November at 15:00 (GMT), this webinar will discuss how co-crystallisation is gaining significant interest as an enabling solution for active pharmaceuticals, which have poor or limiting bioavailability, and as a mechanism for intellectual property (IP) protection.

This webinar in the eighth Concept Life Sciences’ series. It sees Concept and Malvern Panalytical bring together two leading industry experts to present recent developments in the chemistry, regulation and characterisation of active pharmaceutical ingredients (API) co-crystals.

Lead chemist at Concept Life Sciences Kim James will discuss co-crystal fundamental concepts, including their design, chemistry, synthesis and scale-up. He will present the advantages conferred to the discovery and development pathway through co-crystals exhibiting enhanced drug-like properties, together with the recent evolution in the US Food and Drug Administration (FDA) approach to these forms, and their viability as development candidates.

The presentation from Malvern Panalytical’s regional X-ray powder diffraction (XRD) product manager in the Europe, Middle East and Africa region (EMEA) Stjepan Prugovecki will then cover the relevance of crystal structure in the characterisation of co-crystals and the methods for determination and refinement of their crystal structure. It will include discussions on structural differences and similarities between co-crystals, salts, polymorphs, hydrates and solvates, as well as the role of crystal structure in intellectual property protection and patents. It will finish with analytical methods for identification and stability assessment of co-crystals in a bulk pharmaceutical product.

This webinar will be hosted by chief technical officer at Concept Life Sciences Simon Bristow, who has more than 25 years’ experience in pharmaceutical development and API process technology research.

The webinar will be of interest to medicinal chemists, process research specialists, pre-formulation and materials characterisation scientists and those involved in pre-clinical drug development. Click here to register.

Quick Contact